Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Can-Fite BioPharma ( (CANF) ) has issued an update.
On November 18, 2025, Can-Fite BioPharma Ltd. announced an agreement with a warrant holder to reduce the exercise price of warrants for 16,666,666 American Depositary Shares from $0.60 to $0.467 per ADS. This move, in exchange for the waiver of certain standstill provisions by the holder, could potentially enhance the attractiveness of the warrants and improve liquidity, reflecting a strategic decision to adjust financial terms in response to market conditions.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
The overall stock score is heavily influenced by Can-Fite BioPharma’s financial struggles, characterized by declining revenues and persistent losses. Technical analysis further indicates bearish momentum, with the stock trading significantly below key moving averages. The absence of valuation metrics due to unprofitability underscores the challenges faced by the company.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company based in Israel, focusing on the development of small molecule drugs for the treatment of inflammatory, cancer, and liver diseases. The company is known for its proprietary drug candidates targeting specific receptors involved in these diseases.
Average Trading Volume: 6,015,700
Technical Sentiment Signal: Sell
Current Market Cap: $15.78M
See more data about CANF stock on TipRanks’ Stock Analysis page.